As we previously reported, the Ontario Court of Appeal affirmed the lower court's decision dismissing Apotex's claims against Eli Lilly under the Ontario and English Statutes of Monopolies, Trademarks Act...

Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada's refusal to add a patent relating to a formulation of Merck's KEYTRUDA...

On January 8, 2021, the Supreme Court of Canada denied leave to Janssen and Kennedy Trust (Docket No. 39099) with respect to the Federal Court

Mark Robbins and François Larose write for World Trademark Review's Country Correspondents - Canada section,

On December 7, 2017, the Federal Court of Appeal upheld Justice Simpson's decision to strike Alexion's pleadings challenging the constitutionality of the PMPRB regime:

INVEGA SUSTENNA (paliperidone palmitate): Janssen v Pharmascience.

As previously reported, the Federal Court of Appeal overturned the Federal Court's conclusion that Apotex failed to mitigate the loss it incurred as a result of Health Canada's tortious conduct...

The world of digital marketing & advertising is fast-paced and always evolving to adopt the latest technology and capitalize on pop culture trends and new media channels.

In October 2020, the Pharmaceutical Advertising Advisory Board (PAAB) released an advisory addressing references to "no sub" or "no substitution" in advertising materials.

On December 10, 2019, the parties to the Canada-United States-Mexico Agreement (commonly referred to as USMCA, or the new NAFTA) signed amendments to the Agreement.

On February 1, 2023, the Minister of Health announced the appointment of Thomas J. Digby as the new Chairperson for the Patented Medicine Prices Review Board (PMPRB)...

Principals Ainslie Parsons and Noel Courage, along with expert international coauthors, recently contributed to an article in The Patent Lawyer Magazine examining how plant breeders and biotechs can protect...

On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement...

Health Canada and the U.S. Food and Drug Administration (FDA) have created a program to support the establishment of a Request for Information Sharing (RIS) program...

In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).

In March 2023, the Minister of Health announced the National Strategy for Drugs for Rare Diseases, which has as its objective to increase access to, and affordability of, effective drugs for rare diseases...

Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview.

The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.

Earlier this year, the Canadian Patent Office announced that it will increase its official fees on January 1, 2024, in some cases by as much as 36%.

On March 30, 2023, the Supreme Court of Canada dismissed Pharmascience's application for leave to appeal (Docket No. 40400) a decision of the Federal Court of Appeal (FCA) upholding the validity...